Latest
Productivity Vs. Compliance: The Balancing Act of ECM in Life Sciences
While digital transformation in life sciences starts with digitization for compliance, it should be seen as a key lever of competitive advantage and success, writes Jaleel Shujath.
China Expedites Price Reduction of Anticancer Drugs
In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.
FDA Struggles to Advance Biosimilars
New Action Plan aims to streamline development, but rebates and reimbursement block market access.
The Patient-Engagement Quest: A Conversation with DIA’s Barbara Lopez Kunz
DIA’s global chief executive talks about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its potential in everyday practice.
Emerging Biotech: Innovation, Location, and Inspiration
Lisa Henderson examines the rise and reach of biopharma in the key Northeast Corridor clusters of Boston, Philadelphia, and New Jersey.
Pharm Exec Video
Behind the Scenes with Kallyope’s Nancy Thornberry
A sneak peek at Pharm Exec's August cover shoot with the New York City-based biotech CEO.
Why One Korean Biotech Picked New Jersey for U.S. Headquarters
New Jersey is still a top pick for companies when it comes to pharma.
Pharm Exec Talks Partnerships with Sanofi
Hear what Sanofi looks for when they decide to form a partnership with another company.
New & Noteworthy
Army Leadership Lessons: Develop Leaders Three Levels Down
Chad Storlie draws on military training to outline how all industries and organizations can create great junior leaders.
Face It. You’re Not a Biotech Anymore
With increasing responsibilities and decision-making post-discovery, the traditional label of “biotech” is changing, writes Lisa Henderson.
The Pulse of Biopharma M&A
New trends report spotlights the promise and cautions for prospective life sciences dealmakers.
The Big Apple’s Fresh Start in Biotech
New York City is emerging as a hotspot for biotech incubators, including one startup whose CEO made the leap from big pharma to forging new discoveries in medical science. Michelle Maskaly reports.
Sales & Marketing
States Expand Transparency & Disclosure Requirements
Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with HCPs.
‘Emerging’ Product Launch Strategies
Commercial leaders can boost product launches with a data-driven roadmap, writes Erik Cruz.
Hitting Your Targets: A Check-up on Data
Provider data delivers insights into customers and drives decisions about where to focus resources, providing opportunities for sales and marketing in life sciences.
eBooks
Emerging BioPharma: Your Guide to Clinical and Commercial Considerations
This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways.
PEspeaks
Who Knows What HTA Really Is?
A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.
States Expand Transparency & Disclosure Requirements
Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with HCPs.
3 Tips for Successful Public-Private Partnerships in Healthcare
A list of three key elements when looking at public-private partnerships to tackle public health challenges.
CEO Spills the Secret to Attracting, Retaining Biotech Talent
One of the most important jobs of a biotech executive is building a strong team that will not only keep a company competitive in the current market, but will also have the stamina to carry it into the future.
News Update
Pharm Exec’s 14th Annual Press Audit: The Opioid Crisis Takes Center Stage
The opioid crisis dominated the news in this year’s annual audit of industry press coverage.
Emerging Pharma Leaders
Interviews
Navigating the Complex Reimbursement and Policy Landscape of Healthcare Access
Tommy Bramley and Kristine Flemister discuss how stakeholders can better help patients and providers navigate barriers around access and affordability in a complex healthcare environment.
The Patient-Engagement Quest: A Conversation with DIA’s Barbara Lopez Kunz
DIA’s global chief executive talks about the current trajectory of patient-centric product development and the need to establish common pathways and metrics to best harness its potential in everyday practice.
Delivering Ground-breaking Innovation to Those Who Need It
Roche's Marcus Gerund is working to bring healthcare to some of the poorest areas of the world.
Regulatory
Who Knows What HTA Really Is?
A recently announced collaboration between EUnetHTA, WHO, and ISPOR brings home the fact that there is still no real agreement on a definition of HTA, writes Reflector.
States Expand Transparency & Disclosure Requirements
Just as biopharma companies are mastering the complexities of the five-year-old federal Open Payments program, state governments are enacting a host of additional marketing and disclosure rules and restrictions on industry interactions with HCPs.
FDA Struggles to Advance Biosimilars
New Action Plan aims to streamline development, but rebates and reimbursement block market access.
From the Editor
From Science to Success
A common thread in our exploration of "Emerging Biopharma" is that these companies need to be those that look beyond pure discovery—and put equal effort into the pivot to potential commercialization.
Blockchain 101 for Pharma Executives
With blockchain still in the potential but not proven area of the pharma enterprise, when is the technology the right choice for you?
|
|---|
|
Sponsored Links
Global
Emerging Collaboration in EU Drug Pricing and Reimbursement: A Beneluxa Case Study
Using the joint price negotiations developed across Europe as the Beneluxa Initiative on Pharmaceutical Policy as a case study, Maude Schmidt and Giovanni Saldutti explore the implications of such intergovernmental initiatives.
Cross-Border Funding in the Life Sciences
Record capital flows across global public and private markets has opened up new channels of investment in early-stage and novel science.
China Expedites Price Reduction of Anticancer Drugs
In an attempt to reduce high drug prices and improve its medical insurance coverage, China has initiated a series of new moves, including the recent zero import tax on a range of anticancer drugs. Jin Zhang reports.
Pharm Exec's Top 50 Companies 2018
Most of the familiar placeholders are holding their ground as they weigh a changing business climate with new opportunities for growth.
Biotech Investment: Reigning in Spain
Over the last decade, Spain has seen a significant growth in venture-capital investment in the life sciences. We explore the driving forces.
Strategy
‘Emerging’ Product Launch Strategies
Commercial leaders can boost product launches with a data-driven roadmap, writes Erik Cruz.
What Issues Are Top of Mind for Smaller Biotech and Emerging Biopharma Companies?
Daniel Patrick discusses the small biotech company journey from an incubator of ideas to the ability to shepherd an R&D asset through its pipeline to achieving commercial success.
Does the Pfizer Restructuring Make Sense?
The Pfizer restructuring will be a case study in whether corporate restructuring & innovation can co-exist or whether M&A is the more viable answer, writes Edward Pratesi.
Technology
Pharma AI Requires a New Approach to Governance
Artificial intelligence adoption by pharma companies in the UK demands a new, agile governance layer, write Tim Wright and Antony Bott.
Optimizing the Digital Opportunity in Biopharmaceutical R&D
If advanced technologies hold the key to at least some of the productivity issues R&D organizations need to overcome, Nicholas Lakin asks what are the best strategies and operating models for exploiting these aids to their fullest potential.
Fixing the Broken Search Process
Traditional scientific search is broken. AI-supported smart searching is the answer, writes Jane Reed.
